Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential. Earlier in ...

Researchers have found in phase 3 ORIGIN 3 trial that investigational dual BAFF/APRIL inhibitor atacicept significantly ...

Panelists discuss how treatment sequencing in immunoglobulin A (IgA) nephropathy will likely evolve toward a risk-stratified approach, beginning with optimized supportive care and renin ...

IgA Nephropathy (IgAN) is a common kidney disease and a main cause of kidney failure and chronic kidney disease. Read more about its symptoms, causes, risk factors, complications and treatments.

IgA nephropathy is all the rage right now in glomerular diseases, and there's just an exponential increase in the number of clinical trials. We have been seeing new drugs be approved, ...

May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases ...

Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

The IgA Nephropathy Foundation is the only organization 100% dedicated to IgA Nephropathy. Founded in 2004, the Foundation provides resources, support, and funding for groundbreaking research, ...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3. NICE's recommendation is based on clinically ...

The randomized, double-blind, placebo-controlled ORIGIN 3 study (ClinicalTrials.gov Identifier: NCT04716231) included 431 patients with IgA nephropathy who were randomly assigned 1:1 to receive ...

The global IgA nephropathy market is in growth due to rising awareness, better diagnostics, and advanced treatments like complement inhibitors. North. Tuesday, 02 January 2024 12:17 GMT.